ERAL1 and neoplasm: This trend on T cell responses was also demonstrated in intratumoral CD8+ T cells in a pmel-1 T cell receptor transgenic mouse model (Supplementary Figure 4), where cytotoxic CD8+CD107ahi were increased in the spleen and tumor upon treatment with HERA-CD40L, while additionally reducing tumor growth by up to 69%.